Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Fuda Cancer Hospital, Guangzhou"
Count: 116
Selected: 0
| NCT ID | Title |
|---|
| NCT03180437 | Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer | ||
| NCT03985462 | Very Small Embryonic-like Stem Cells for Ovary | ||
| NCT03976206 | Very Small Embryonic-like Stem Cells for Facial Skin Antiaging | ||
| NCT03975101 | Very Small Embryonic-like Stem Cells for Knee Osteoarthritis | ||
| NCT03973021 | Very Small Embryonic-like Stem Cells for Erectile Dysfunction | ||
| NCT03183232 | Safety and Efficiency of γδ T Cell Against Lung Cancer | ||
| NCT03183219 | Safety and Efficiency of γδ T Cell Against Liver Cancer | ||
| NCT03183206 | Safety and Efficiency of γδ T Cell Against Breast Cancer | ||
| NCT03357315 | Mix Vaccine for Metastatic Sarcoma Patients | ||
| NCT03357289 | Mix Vaccine for Metastatic Kidney Cancer | ||
| NCT03357276 | Mix Vaccine for Metastatic Colorectal Cancer | ||
| NCT02425748 | Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation) | ||
| NCT02449135 | Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma | ||
| NCT04393220 | Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma | ||
| NCT03673137 | Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC | ||
| NCT02430779 | Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms | ||
| NCT02430766 | Irreversible Electroporation(IRE) For Unresectable Lymph Node Metastases(Close to Nerve) | ||
| NCT02430753 | Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency | ||
| NCT02430701 | Irreversible Electroporation(IRE) For Unresectable Esophageal Neoplasms | ||
| NCT02430688 | Irreversible Electroporation(IRE) For Unresectable Extremities Neoplasms | ||
| NCT02430675 | Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms | ||
| NCT02430662 | Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms | ||
| NCT02430636 | Irreversible Electroporation(IRE) For Unresectable Stomach Neoplasms | ||
| NCT02430623 | Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms | ||
| NCT02430610 | Irreversible Electroporation(IRE) For Uterine Cervical Neoplasms | ||
| NCT02430597 | Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms | ||
| NCT02425059 | Irreversible Electroporation(IRE) For Unresectable Rectal Neoplasms | ||
| NCT02352935 | Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function | ||
| NCT02343835 | Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer | ||
| NCT02340858 | Percutaneous Irreversible Electroportion for Unresectable Breast Cancer | ||
| NCT02335827 | Irreversible Electroporation(IRE) For Unresectable Renal Tumors | ||
| NCT02335112 | Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms | ||
| NCT02333773 | Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli | ||
| NCT02332551 | Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder | ||
| NCT02329106 | Percutaneous Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome | ||
| NCT02981719 | Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer | ||
| NCT03818347 | Hydrogen Gas for Cancer Rehabilitation | ||
| NCT03554395 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer | ||
| NCT03540199 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer | ||
| NCT03524274 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer | ||
| NCT03524261 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer | ||
| NCT03509298 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer | ||
| NCT03501056 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer | ||
| NCT03484962 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer | ||
| NCT02857920 | Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors | ||
| NCT04406610 | CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients | ||
| NCT03252171 | CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients | ||
| NCT02723942 | CAR-T Cell Immunotherapy for HCC Targeting GPC3 | ||
| NCT02575261 | CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients | ||
| NCT02547961 | Chimeric Antigen Receptor-Modified T Cells for Breast Cancer |
